about
Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell linesNeoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumabThe Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor FamilyRecent advances in the development of anti-HER2 antibodies and antibody-drug conjugatesMechanisms of action of therapeutic antibodies for cancerIgE-based Immunotherapy of Cancer -A Comparative Oncology ApproachOpen-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative meTrastuzumab has preferential activity against breast cancers driven by HER2 homodimers.Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer.Local variations of HER2 dimerization in breast cancer cells discovered by correlative fluorescence and liquid electron microscopyEpidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer.Pertuzumab for the treatment of ovarian cancer.Pertuzumab for the treatment of metastatic breast cancer.Liquid-phase electron microscopy of molecular drug response in breast cancer cells reveals irresponsive cell subpopulations related to lack of HER2 homodimers.Blockade of a key region in the extracellular domain inhibits HER2 dimerization and signaling.In vivo and in vitro activity of an immunoglobulin Fc fragment (Fcab) with engineered Her-2/neu binding sites.Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6KPertuzumab and trastuzumab: the rationale way to synergy.Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine.Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature.Acquired Resistance to Drugs Targeting Tyrosine Kinases.A novel ErbB2 epitope targeted by human antitumor immunoagents
P2860
Q24293655-3DA06F22-AF4E-4EEC-A955-6D9510E85BEAQ26764879-A2683AB3-F357-4792-AB46-4229E78AA73EQ28073335-8A4D1625-D1A1-41BE-AA5E-47438A812F38Q28083123-8000F2C5-FF3F-4EBE-9E71-01B69D17E070Q28385366-CE2C56DC-8E30-40B3-9D52-E91D59BD1177Q28655505-5F498C1B-1CB8-4927-9087-084FCBB6672AQ30376023-5C19CFDC-0E04-4E2F-8AF1-9BFD59E0909CQ35566231-84C90093-0D52-4F52-BF12-81A93A051207Q35999582-B7662A99-84CD-495C-838D-55F5272CEB9CQ36284765-DDC54018-4FC7-4A83-A062-1E01985A34DFQ36302860-D37B3258-3CB2-4242-BDBD-8BB49CDE2CD2Q37750891-54D3F9C7-11B7-4BF6-8E09-43A16B45B850Q38132237-77A832CA-0CD7-4671-9BE6-7DE5C7D64F11Q38695293-F25CFF82-DD30-46D6-9BE5-2ADC4E48D729Q38885404-75630ED2-6453-4F0F-AF9B-0C0B67E59B41Q38997358-F2E79D2E-E835-49A6-922C-FDAA72C33A05Q39501392-8FBB0176-7363-4ECD-8CF8-7DA0DCB04031Q39664471-093EA24C-48CA-45C0-B736-ACE8CF19EB93Q39701009-EE125887-CE04-4C21-8F44-1201496BE112Q41603225-229F7EFA-24F3-456D-9EFF-33679886B004Q46688979-0DC476BA-DD14-4234-A7EF-416D175090B0Q53701267-4254CE3B-EB65-41F5-89D1-735E190A4901Q57628597-90223DF9-429C-4C91-B9E7-BFC6F07A2814
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
A new therapeutic antibody masks ErbB2 to its partners
@ast
A new therapeutic antibody masks ErbB2 to its partners
@en
A new therapeutic antibody masks ErbB2 to its partners
@nl
type
label
A new therapeutic antibody masks ErbB2 to its partners
@ast
A new therapeutic antibody masks ErbB2 to its partners
@en
A new therapeutic antibody masks ErbB2 to its partners
@nl
prefLabel
A new therapeutic antibody masks ErbB2 to its partners
@ast
A new therapeutic antibody masks ErbB2 to its partners
@en
A new therapeutic antibody masks ErbB2 to its partners
@nl
P3181
P1433
P1476
A new therapeutic antibody masks ErbB2 to its partners
@en
P2093
Nancy E Hynes
P304
P3181
P356
10.1016/S1535-6108(04)00088-1
P407
P50
P577
2004-04-01T00:00:00Z